Antibiotics | Countries (%) | ||
---|---|---|---|
Nepal (n = 42) | Bangladesh (n = 56) | Both countries (n = 98) | |
True Single Resistance | |||
 Metronidazolea | 9/42 (21.4) | 6/56 (10.7) | 15/98 (15.3) |
 Levofloxacina | 0/42 (0.0) | 1/56 (1.8) | 1/98 (1.0) |
Double Resistanceb | |||
 Levofloxacin+metronidazole | 3/42 (7.1) | 2/56 (3.6) | 5/98 (5.1) |
 Levofloxacin+garenoxacin | 0/42 (0.0) | 1/56 (1.8) | 1/98 (1.0) |
 Rifaximin+garenoxacin | 2/42 (4.8) | 0/56 (0.0) | 1/98 (1.0) |
 Rifaximin+metronidazole | 8/42 (19.0) | 7/56 (12.5) | 15/98 (15.3) |
 Rifaximin+clarithromycin | 1/42 (2.4) | 0/56 (0.0) | 1/98 (1.0) |
 Clarithromycin+metronidazole | 0/42 (0.0) | 3/56 (5.4) | 3/98 (3.0) |
Triple Resistance | |||
 Clarithromycin+levofloxacin+metronidazole | 1/42 (2.4) | 2/56 (3.6) | 3/98 (3.1) |
 Clarithromycin+metronidazole+rifaximin | 2/42 (4.8) | 1/56 (1.8) | 3/98 (3.1) |
 Levofloxacin+metronidazole+garenoxacin | 2/42 (4.8) | 3/56 (5.4) | 5/98 (5.1) |
 Levofloxacin+metronidazole+rifaximin | 3/42 (7.1) | 4/56 (7.1) | 7/98 (7.1) |
Quadruple Resistance | |||
 Clarithromycin+levofloxacin+metronidazole+rifaximin | 0/42 (0.0) | 1/56 (1.8) | 1/98 (1.0) |
 Clarithromycin+levofloxacin+metronidazole +garenoxacin | 2/42 (4.8) | 2/56 (3.6) | 4/98 (4.1) |
 Clarithromycin+metronidazole+rifaximin+garenoxacin | 1/42 (2.4) | 0/56 (0.0) | 1/98 (1.0) |
 Levofloxacin+metronidazole+rifaximin+garenoxacin | 4/42 (9.5) | 8/56 (14.3) | 12/98 (12.2) |
Quintuple Resistance | |||
 Clarithromycin+levofloxacin+metronidazole+garenoxacin+rifaximin | 0/42 (0.0) | 12/56 (21.4) | 12/98 (12.2) |
 Amoxicillin+levofloxacin+metronidazole+garenoxacin+rifaximin | 0/42 (0.0) | 1/56 (1.8) | 1/98 (1.0) |
Sextuple Resistance | |||
 Clarithromycin+levofloxacin+metronidazole+garenoxacin+rifaximin+sitafloxacin | 2/42 (4.8) | 0/56 (0.0) | 2/98 (2.0) |
 Amoxicillin+levofloxacin+metronidazole+garenoxacin+rifaximin+sitafloxacin | 0/42 (0.0) | 1/56 (1.8) | 1/98 (1.0) |